Related Experiment Video
Updated: Aug 5, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect
Abstract:
Forty patients wtih pituitary adenomas, i.e. 22 prolactinomas, 13 acromegalies, 5 non-secreting adenomas, were submitted to bromocriptine therapy 19.3 +/- 1.7 mg/day (mean +/- SEM) (range 7.5-40.0 mg/day) for 5 to 41 months (10.1 +/- 1.31). Remission of the tumoral mass was documented by air tomograms (PETG) or computerized tomograms (CT) in all but one prolactinomas and in 2 mixed HGH and PRL-secreting adenomas. Six empty sella syndromes (ESS) were produced, 4 of them during primary chemotherapy. Serum PRL decreased to normal in all but 3 prolactinomas, and serum HGH levels in 5 out of 13 acromegalies. Bromocriptine withdrawal was followed by a rapid increase of serum PRL into the pathological range, without a rapid reexpansion of the tumoral remnants: GT or surgical exploration of 4 cases, remitted until ESS showed a minimal evolution along 8 months after bromocriptine withdrawal. It is suggested that the antitumoral effect of bromocriptine is specific to lactotrophic cells and at least partially irreversible.
Related Concept Videos
Cholinergic Antagonists: Pharmacokinetics
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Psychosis: Goals of Pharmacotherapy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Therapeutic Drug Monitoring: Affecting Factors

